Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, Opt-in with us: www.register.msviewsandnews.org

Please visit our MS learning channel on YouTube, which provides hundreds of MS topics presented by MS Experts across the USA, from many of our video recorded education programs. Archived here: www.youtube.com/msviewsandnews -- PLUS Visit our Social media platforms: Facebook, Twitter, and Instagram

~~ Left side of this blog shows resources, needed by many. Easiest way to find topic or articles is to use our 'search by topic' tool, to find specific information ~~

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Tuesday, March 31, 2009

Genzyme and Bayer HealthCare Enter New Strategic Agreement over CAMPATH

Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis

Acquires Bayer’s Hematologic Oncology Portfolio

First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment

  • Tuesday March 31, 2009, 8:00 am EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation announced today that it has entered into an agreement to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential break-though treatment for multiple sclerosis (MS). Bayer will continue to fund a portion of alemtuzumab’s development in MS and will retain an option to co-promote the product in MS upon approval. In addition, Genzyme will assume sole responsibility for worldwide sales and marketing for Campath in B-cell chronic lymphocytic leukemia (CLL), where it is indicated for use as a single agent in first-line and previously-treated patients with this disease. Bayer will retain the right to develop and commercialize alemtuzumab in solid organ transplant indications.

The agreement further expands Genzyme’s hematologic oncology commercial presence beyond Campath through the addition of Fludara® (fludarabine) and Leukine® (sargramostim), and provides an opportunity to integrate members of Bayer’s experienced commercial team for all three drugs into Genzyme’s global operations. Genzyme will acquire a new, Seattle-area Leukine manufacturing facility for $75 to $100 million and hire the plant’s operating personnel following FDA plant approval, which is expected in 2010.

Continue reading from Yahoo Finance

.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

No comments: